{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=HER2-Negative+Breast+Carcinoma&page=6",
    "query": {
      "condition": "HER2-Negative Breast Carcinoma",
      "page": 6
    },
    "page_size": 10
  },
  "pagination": {
    "page": 6,
    "page_size": 10,
    "total_count": 689,
    "total_pages": 69,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=HER2-Negative+Breast+Carcinoma&page=7&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=HER2-Negative+Breast+Carcinoma&page=5&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-19T05:13:36.029Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01862081",
      "title": "A Dose-escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of GDC-0032 in Combination With Docetaxel or With Paclitaxel in Patients With HER2-negative Locally Recurrent or Metastatic Breast Cancer or Non-small Cell Lung Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Breast Cancer, Non-small Lung Cancer"
      ],
      "interventions": [
        {
          "name": "Docetaxel",
          "type": "DRUG"
        },
        {
          "name": "GDC-0032",
          "type": "DRUG"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Genentech, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 80,
      "start_date": "2013-07-16",
      "completion_date": "2017-06-09",
      "has_results": false,
      "last_update_posted_date": "2017-11-28",
      "last_synced_at": "2026-11-19T05:13:36.029Z",
      "location_count": 10,
      "location_summary": "Tampa, Florida • Boston, Massachusetts • Detroit, Michigan + 5 more",
      "locations": [
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01862081"
    },
    {
      "nct_id": "NCT06388122",
      "title": "DiviTum®TKa: A Biomarker Assay for Efficacy in HR+ Breast Cancer Patients",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "HER2-negative Breast Cancer",
        "Hormone-receptor-positive Breast Cancer",
        "Metastatic Breast Cancer",
        "Anatomic Stage II Breast Cancer AJCC v8",
        "Anatomic Stage III Breast Cancer AJCC v8",
        "Anatomic Stage IV Breast Cancer AJCC v8",
        "HER2 Negative Breast Carcinoma",
        "Hormone Receptor Positive Breast Carcinoma",
        "Metastatic Breast Carcinoma"
      ],
      "interventions": [
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 100,
      "start_date": "2024-04-30",
      "completion_date": "2031-06-15",
      "has_results": false,
      "last_update_posted_date": "2026-06-01",
      "last_synced_at": "2026-11-19T05:13:36.029Z",
      "location_count": 1,
      "location_summary": "Jacksonville, Florida",
      "locations": [
        {
          "city": "Jacksonville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06388122"
    },
    {
      "nct_id": "NCT03872505",
      "title": "Pre-operAtive Non-Anthracycline Chemotherapy, Durvalumab +/- RAdiation Therapy in Triple Negative Breast Cancer",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Breast Cancer",
        "Triple Negative Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Durvalumab",
          "type": "DRUG"
        },
        {
          "name": "Radiation Therapy",
          "type": "RADIATION"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION"
      ],
      "sponsor": "Cedars-Sinai Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2022-07",
      "completion_date": "2027-07",
      "has_results": false,
      "last_update_posted_date": "2021-08-25",
      "last_synced_at": "2026-11-19T05:13:36.029Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03872505"
    },
    {
      "nct_id": "NCT02260531",
      "title": "Cabozantinib +/- Trastuzumab In Breast Cancer Patients w/ Brain Metastases",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Breast Cancer",
        "Brain Tumor - Metastatic"
      ],
      "interventions": [
        {
          "name": "Cabozantinib",
          "type": "DRUG"
        },
        {
          "name": "Trastuzumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Dana-Farber Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 36,
      "start_date": "2014-11",
      "completion_date": "2020-03-17",
      "has_results": true,
      "last_update_posted_date": "2021-05-20",
      "last_synced_at": "2026-11-19T05:13:36.029Z",
      "location_count": 2,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02260531"
    },
    {
      "nct_id": "NCT02208375",
      "title": "mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and Ovarian",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "BRCA1 Mutation Carrier",
        "BRCA2 Mutation Carrier",
        "Endometrial Adenocarcinoma",
        "Estrogen Receptor Negative",
        "HER2/Neu Negative",
        "High Grade Ovarian Serous Adenocarcinoma",
        "Progesterone Receptor Negative",
        "Recurrent Breast Carcinoma",
        "Recurrent Fallopian Tube Carcinoma",
        "Recurrent Ovarian Carcinoma",
        "Recurrent Primary Peritoneal Carcinoma",
        "Recurrent Uterine Corpus Carcinoma",
        "Stage III Uterine Corpus Cancer AJCC v7",
        "Stage IV Breast Cancer AJCC v6 and v7",
        "Stage IV Uterine Corpus Cancer AJCC v7",
        "Triple-Negative Breast Carcinoma"
      ],
      "interventions": [
        {
          "name": "Capivasertib",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Olaparib",
          "type": "DRUG"
        },
        {
          "name": "Pharmacological Study",
          "type": "OTHER"
        },
        {
          "name": "Vistusertib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 159,
      "start_date": "2014-11-11",
      "completion_date": "2028-06-30",
      "has_results": false,
      "last_update_posted_date": "2026-09-04",
      "last_synced_at": "2026-11-19T05:13:36.029Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02208375"
    },
    {
      "nct_id": "NCT05304962",
      "title": "FIH Study of RGT-419B Alone and With Endocrine Therapy in HR-Positive, HER2-Negative Advanced/Metastatic Breast Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "RGT-419B",
          "type": "DRUG"
        },
        {
          "name": "RGT-419B in combination with hormonal therapy",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Regor Pharmaceuticals Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 64,
      "start_date": "2022-03-04",
      "completion_date": "2027-03-31",
      "has_results": false,
      "last_update_posted_date": "2026-08-12",
      "last_synced_at": "2026-11-19T05:13:36.029Z",
      "location_count": 8,
      "location_summary": "La Jolla, California • Los Angeles, California • Port Saint Lucie, Florida + 5 more",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Port Saint Lucie",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05304962"
    },
    {
      "nct_id": "NCT01272037",
      "title": "Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Breast Ductal Carcinoma In Situ",
        "Invasive Breast Carcinoma",
        "Multicentric Breast Carcinoma",
        "Multifocal Breast Carcinoma",
        "Synchronous Bilateral Breast Carcinoma"
      ],
      "interventions": [
        {
          "name": "Anastrozole",
          "type": "DRUG"
        },
        {
          "name": "Exemestane",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Letrozole",
          "type": "DRUG"
        },
        {
          "name": "Quality-of-Life Assessment",
          "type": "OTHER"
        },
        {
          "name": "Systemic Chemotherapy",
          "type": "DRUG"
        },
        {
          "name": "Tamoxifen Citrate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 5018,
      "start_date": "2011-02-28",
      "completion_date": "2027-01-08",
      "has_results": true,
      "last_update_posted_date": "2026-11-13",
      "last_synced_at": "2026-11-19T05:13:36.029Z",
      "location_count": 1435,
      "location_summary": "Anniston, Alabama • Birmingham, Alabama • Mobile, Alabama + 881 more",
      "locations": [
        {
          "city": "Anniston",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01272037"
    },
    {
      "nct_id": "NCT06351332",
      "title": "ZAP-IT: ZN-c3 + Carboplatin + Pembrolizumab in mTNBC",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Breast Cancer",
        "Breast Cancer Female",
        "Triple Negative Breast Cancer",
        "Hormone Receptor Negative Malignant Tumor Breast Triple",
        "HER2-negative Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Azenosertib",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Filipa Lynce, MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 7,
      "start_date": "2024-05-01",
      "completion_date": "2026-02-24",
      "has_results": false,
      "last_update_posted_date": "2026-06-04",
      "last_synced_at": "2026-11-19T05:13:36.029Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06351332"
    },
    {
      "nct_id": "NCT00827567",
      "title": "Trial of RAD001 in Triple Negative Metastatic Breast Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "RAD 001",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Milton S. Hershey Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 6,
      "start_date": "2009-04",
      "completion_date": "2011-02",
      "has_results": true,
      "last_update_posted_date": "2014-01-13",
      "last_synced_at": "2026-11-19T05:13:36.029Z",
      "location_count": 1,
      "location_summary": "Hershey, Pennsylvania",
      "locations": [
        {
          "city": "Hershey",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00827567"
    },
    {
      "nct_id": "NCT02258464",
      "title": "Study of Radium-223 Dichloride Versus Placebo and Hormonal Treatment as Background Therapy in Subjects With Bone Predominant HER2 (Human Epidermal Growth Factor Receptor 2) Negative Hormone Receptor Positive Metastatic Breast Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Breast Neoplasms"
      ],
      "interventions": [
        {
          "name": "Radium-223 dichloride (Xofigo, BAY88-8223)",
          "type": "DRUG"
        },
        {
          "name": "Placebo (saline)",
          "type": "DRUG"
        },
        {
          "name": "Background hormonal therapy",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Bayer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 99,
      "start_date": "2015-03-02",
      "completion_date": "2019-08-13",
      "has_results": true,
      "last_update_posted_date": "2020-08-10",
      "last_synced_at": "2026-11-19T05:13:36.029Z",
      "location_count": 11,
      "location_summary": "Bakersfield, California • La Jolla, California • Aurora, Colorado + 8 more",
      "locations": [
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Cedar Rapids",
          "state": "Iowa"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02258464"
    }
  ]
}